CENICRIVIROC FOR TREATING FIBROSIS Russian patent published in 2020 - IPC A61K31/55 A61K45/00 A61P1/16 A61P13/12 A61P31/18 A61P31/12 A61K31/194 

FIELD: medicine.

SUBSTANCE: group of inventions is intended for treating hepatic fibrosis or renal fibrosis in a subject. That is ensured by combined administration of a pharmaceutical composition containing a therapeutically effective amount of Cenicriviroc or a salt thereof; fumaric acid; and one or more additional active agents. Said additional agents are selected from a group consisting of an antiretroviral agent, an immune suppressing agent and an antifibrotic agent. Said hepatic fibrosis is associated with non-cirrhotic hepatic fibrosis, cirrhosis, non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD). In another embodiment, a method of treating NASH in a subject is provided, comprising administering a therapeutically effective amount of Cenicriviroc or a salt thereof; wherein the non-alcoholic steatohepatitis is associated with a CCR5-tropic HIV-1 infection.

EFFECT: using the group of inventions enables providing higher clinical effectiveness in fibrosis and NASH in a subject.

13 cl, 38 tbl, 26 ex, 56 dwg